JPS6130213B2 - - Google Patents
Info
- Publication number
- JPS6130213B2 JPS6130213B2 JP52134958A JP13495877A JPS6130213B2 JP S6130213 B2 JPS6130213 B2 JP S6130213B2 JP 52134958 A JP52134958 A JP 52134958A JP 13495877 A JP13495877 A JP 13495877A JP S6130213 B2 JPS6130213 B2 JP S6130213B2
- Authority
- JP
- Japan
- Prior art keywords
- cholesterol
- blood cells
- blood cell
- hemolysis
- cell membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 53
- 210000000601 blood cell Anatomy 0.000 claims description 52
- 239000012528 membrane Substances 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 31
- 235000012000 cholesterol Nutrition 0.000 claims description 27
- 230000003204 osmotic effect Effects 0.000 claims description 17
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000002949 hemolytic effect Effects 0.000 claims description 5
- 150000003839 salts Chemical group 0.000 claims description 4
- 206010018910 Haemolysis Diseases 0.000 description 26
- 230000008588 hemolysis Effects 0.000 description 26
- HSFWRNGVRCDJHI-UHFFFAOYSA-N Acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 1
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000009601 hereditary spherocytosis Diseases 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 229940116357 potassium thiocyanate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13495877A JPS5468291A (en) | 1977-11-10 | 1977-11-10 | Method of measuring osmotic pressure resistance of corpuscle membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13495877A JPS5468291A (en) | 1977-11-10 | 1977-11-10 | Method of measuring osmotic pressure resistance of corpuscle membrane |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP23521284A Division JPS60259960A (ja) | 1984-11-09 | 1984-11-09 | 血球膜中のコレステロ−ルの定量方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5468291A JPS5468291A (en) | 1979-06-01 |
| JPS6130213B2 true JPS6130213B2 (sv) | 1986-07-11 |
Family
ID=15140543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13495877A Granted JPS5468291A (en) | 1977-11-10 | 1977-11-10 | Method of measuring osmotic pressure resistance of corpuscle membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5468291A (sv) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5649681U (sv) * | 1979-09-26 | 1981-05-01 | ||
| JPS60259960A (ja) * | 1984-11-09 | 1985-12-23 | Sanki Eng Kk | 血球膜中のコレステロ−ルの定量方法 |
| IL85532A (en) * | 1987-03-13 | 1992-03-29 | Coulter Electronics | Method and lytic reagent system for isolation,identification and/or analysis of leukocytes from whole blood samples |
| US5155044A (en) * | 1987-03-13 | 1992-10-13 | Coulter Electronics, Inc. | Lysing reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples |
| FR2873925B1 (fr) * | 2004-08-05 | 2006-10-13 | Erytech Pharma Soc Par Actions | Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5219611A (en) * | 1975-08-07 | 1977-02-15 | Mitsubishi Chem Ind Ltd | Process for recovery of butanediol and/ or butenediol |
-
1977
- 1977-11-10 JP JP13495877A patent/JPS5468291A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5219611A (en) * | 1975-08-07 | 1977-02-15 | Mitsubishi Chem Ind Ltd | Process for recovery of butanediol and/ or butenediol |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5468291A (en) | 1979-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen et al. | Serum lactic dehydrogenase isozyme patterns in cardiovascular and other diseases, with particular reference to acute myocardial infarction | |
| Ray et al. | Experiments on the degradation of lipoproteins from serum | |
| Kostner et al. | Investigation of the abnormal low-density lipoproteins occurring in patients with obstructive jaundice | |
| Zade‐Oppen | Posthypertonic hemolysis in sodium chloride systems | |
| Aspelin | Effect of ionic and non-ionic contrast media on red cell deformability in vitro | |
| Bojesen et al. | Binding of arachidonate and oleate to bovine serum albumin. | |
| Murphy | Hemoglobin CC disease: Rheological properties of erythrocytes and abnormalities in cell water | |
| Salt et al. | The applications of serum lipoprotein electrophoresis in paediatric practice | |
| Tillmann et al. | Rheological properties of young and aged human erythrocytes | |
| Brenner et al. | On estimating colloid osmotic pressure in pre-and postglomerular plasma in the rat | |
| Martınez-Subiela et al. | Effects of haemolysis, lipaemia, bilirubinaemia and fibrinogen on protein electropherogram of canine samples analysed by capillary zone electrophoresis | |
| Yeh et al. | Nuclear magnetic resonance studies on intracellular sodium in human erythrocytes and frog muscle | |
| JPS6130213B2 (sv) | ||
| Roy et al. | A simple method for the quantitative determination of serum haptoglobin | |
| Parker et al. | Dog red blood cells: Na and K diffusion potentials with extracellular ATP. | |
| Neuhaus et al. | Haemorheology and exercise: intrinsic flow properties of blood in marathon running | |
| US4158049A (en) | Antigen fraction of Schistosoma mansoni eggs suitable for testing for schistosomiasis | |
| Artiss et al. | Problems with measurements caused by high concentrations of serum solids | |
| Liu et al. | Charge density profiling of circulating human low‐density lipoprotein particles by capillary zone electrophoresis | |
| Numano et al. | Changes in the plasma levels of thromboxane B2 and cyclic nucleotides in patients with Takayasu disease | |
| Whisnant Jr et al. | Primary idiopathic myoglobinuria in a Negro female: its implications and a new method of laboratory diagnosis | |
| JP3686482B2 (ja) | ヘモグロビンａ１ｃの管理試料 | |
| Birgegård | Serum ferritin: physiological and methodological studies | |
| JPS60259960A (ja) | 血球膜中のコレステロ−ルの定量方法 | |
| Yeung et al. | Capillary electrophoresis for the determination of albumin binding capacity and free bilirubin in jaundiced neonates |